卡培他滨致手足综合征的发生规律及治疗进展

www.yongyao.net　　2009-8-20 11:17:54　　来源：　　责任编辑：

分享到：

4 参考文献
[1] Lokich JJ, Moore C.Chemotherapy- associated palmar - plantar erythrodysesthesia syndrome[J].Ann Intern Med, 1984, 101(6):798- 799.
[2] Blum JL, Jones SE, Buzdar AU, et al.Multicenter phase IIstudy of capecitabine in paclitaxel- refractory etastatic breast cancer[J].J Clin Oncol, 1999, 17(2): 485- 493.
[3] Blum JL, Dieras V, Lo Russo PM, et al.Multicenter, phase IIstudy of capecitabine in taxane- pretreated metastatic breast carcinoma patients[J].Cancer, 2001, 92(7):1759- 1768.
[4] Reichardt P, Von Minckwitz G, Thuss - Patience PC, et al.Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment
with a taxane - containing therapy [J].Ann Oncol,2003, 14(8):1227- 1233.
[5] Hoff PM, Ansari R, Batist G, et al.Comparison of oralcapecitabine versus intravenous fluorouracil plus leucovorinas first- line treatment in 605 patients with metastatic colorectal
cancer: results of a randomized Phase III study[J].JClin Oncol, 2001, 19(8):2282- 2292.
[6] Van Cutsem E, Twelves C, Cassidy J, et al.Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large
Phase III study[J].J Clin Oncol, 2001, 19(21):4097- 4106.
[7] OShaughnessy J, Miles D, Vukelja S, et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phase III trial results [J].J Clin Oncol, 2002, 20 (12):2812-2823.
[8] Miller KD, Chap LI, Holmes FA, et al.Randomized phase IIItrial of capecitabine compared with bevacizumab pluscapecitabine in patients with previously treated metastatic
breast cancer[J].J Clin Oncol, 2005, 23(4):792- 799.
[9] Scheithauer W, McKendrick J, Begbie S, et al.Oralcapecitabine as an alternative to i.v.5 - fluorouracil - based adjuvant therapy for colon cancer:safety results of a randomized,
phase III trial [J].Ann Oncol, 2003, 14 (12):1735-1743.
[10] Twelves C,Wong A, Nowacki MP, et al.Capecitabine as adjuvant treatment for stage III colon cancer [J].N Engl JMed, 2005, 352(26):2696- 2704.
[11] 王涛, 江泽飞, 宋三泰, 等.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J]. 癌症进展杂志, 2004, 2(4):258- 260.
[12] Narasimhan P, Narasimhan S, Hitti IF, et al.Serious hand -and - foot syndrome in black patients treated with capecitabine:report of 3 cases and review of the literature[J].Cutis, 2004, 73(2):101- 106.
[13] Hennessy BT, Gauthier AM, Michaud LB, et al.Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer:retrospective analysis of patientstreated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature [J].Ann Oncol,
2005, 16(8):1289- 1296.
[14] Abushullaih S, Saad ED, Munsell M, et al.Incidence and severity of hand - foot syndrome in colorectal cancer patients treated with capecitabine:a single- institution experience[J].Cancer Invest, 2002, 20(1):3- 10.
[15] Heo YS, Chang HM, Kim TW, et al.Hand- foot syndrome in patients treated with apecitabine - containing combination chemotherapy[J].J Clin Pharmacol, 2004, 44(10):1166- 1172.
[16] Lassere Y, Hoff P.Management of hand - foot syndrome in patients treated with capecitabine (Xeloda).Eur J OncolNurs, 2004, 8(Suppl 1):S31- 40.
[17] Sarah M, Brad L, Fred H.Management of hand - foot syndrome induced by capecitabine[J].J Oncol Pharm Practice,2006, 12(3):131- 141.
[18] Ploylearmsaeng SA, Fuhr U, Jetter A.How many anticancer chemotherapy with fluorouracil be individualised [J].JClin- Pharmacokinet, 2006, 45(6):567- 592.
[19] Mortimer JE, Lauman MK, Tan B, et al.Pyridoxine treatment and prevention of hand- and- foot syndrome in patients receiving capecitabine [J].J Oncol Pharm Pract,2003, 9:161-
166.
[20] Lin E, Morris JS, Ayers GD.Effect of celecoxib on capecitabin- induced hand- foot syndrome and antitumor activity[J].Oncology(Williston Park), 2002, 16(12 SupplNo 14):31- 37.
[21] Lin EH, Ayer G, Crane C, et al.Celecoxib, a selective cyclooxygenase-2 (COX- 2) inhibitor, ameliorated capecitabine(Xeloda) hand and foot syndrome (HFS) and enhanced survival
in metastatic colorectal cancer [J].Proc Am Soc ClinOncol, 2004, 23:3584.
[22] Kara IO, Sahin B, Erkisi M.Palmar- plantar erythrodysesthesiadue to docetaxel - capecitabine therapy is treated with vitamin E without dose reduction[J].Breast, 2006, 15(3):414-424.
[23] Pendharkar D, Goyal H.Novel and effective management of capecitabine induced hand foot syndrome [J].Proc Am SocClin Oncol, 2004, 23:8105.